The Relationship Between the Liver and Pancreas

The liver and pancreas are two of the most tightly connected organs in the body, linked by shared blood supply, a common duct system, constant hormonal signaling, and even a shared embryological origin. They begin as the same cluster of cells in the developing embryo, and they remain in close conversation for life. When one organ is in trouble, the other usually feels it, whether through disrupted hormone handling, backed-up bile, or the accumulation of excess fat. Understanding how these organs depend on each other explains a surprising range of diseases, from gallstone pancreatitis to a form of diabetes that is caused not by the pancreas but by the liver itself.

They Start as the Same Cells

In early embryonic development, the liver and pancreas arise from the same region of tissue. Before either organ takes shape, a stretch of cells in the foregut endoderm expresses a transcription factor called Prox1, and detailed analysis of whole embryos has confirmed that Prox1 expression in this early endoderm is restricted to the regions that will become the liver and pancreas, making it one of the earliest known markers for this shared territory.¹ Experiments on embryonic tissue have further shown that the liver and the ventral pancreas are specified at the same time and from the same general population of cells. When researchers isolated that patch of foregut endoderm and let it develop without outside signals, the default program those cells activated was the pancreatic one, suggesting the liver fate is an override imposed by neighboring signals rather than an independent blueprint.²

This common ancestry is not just a developmental curiosity. It helps explain why the two organs share so much molecular machinery, why certain diseases target both organs simultaneously, and why therapeutic strategies aimed at one organ often ripple through the other.

The Portal Vein and Insulin Delivery

Once development is complete, the most important physical link between the pancreas and liver is the portal vein. Blood draining from the pancreas flows directly into the liver before reaching the rest of the body, and this arrangement has enormous consequences for how insulin works. The pancreas secretes insulin in discrete bursts roughly every five minutes into the portal vein, and these pulses are dampened early in the course of both type 1 and type 2 diabetes.³ Because of this direct plumbing, insulin concentrations at the liver are roughly three times higher than in the general circulation.⁴

That gradient matters. The liver is the body’s central glucose warehouse, storing and releasing sugar in response to insulin and other signals. Having first access to high-concentration insulin pulses allows the liver to respond quickly and precisely. Injected insulin, by contrast, reaches all tissues at the same concentration and enters the liver at much lower levels than a healthy pancreas would deliver. This mismatch is one reason why managing blood sugar with injected insulin is inherently less elegant than having a working pancreas.

How the Liver Filters Insulin

The liver does not just receive insulin; it actively removes a large share of it before the hormone ever reaches the rest of the body. This process, called first-pass hepatic insulin extraction, is surprisingly variable. In a study that directly measured extraction in healthy animals by comparing insulin infused through the portal vein versus a peripheral vein, first-pass extraction ranged from about 22% to 77%, with an average near 50%.⁵ That wide range means two individuals with identical pancreatic insulin output can end up with very different circulating insulin levels, depending on how aggressively their liver clears the hormone. The same study found that this extraction rate correlated with both fasting insulin levels and overall insulin sensitivity, suggesting the liver is not a passive filter but an active regulator of how much insulin the body sees.⁵

When this clearance process breaks down, the consequences echo across both organs. Reduced hepatic insulin clearance can lead to chronically elevated insulin in the bloodstream, which over time may worsen insulin resistance and stress pancreatic beta cells, nudging the system toward metabolic disease.⁶

The Liver Sends Signals Back to the Pancreas

The conversation between these organs is not one-directional. The liver produces a hormone called FGF21, which circulates to many tissues, including the pancreatic islets where insulin-producing beta cells reside. In rat islets and beta-cell lines, FGF21 increased insulin gene expression and insulin protein content, and it partially protected beta cells from death caused by toxic fat and inflammatory signals.⁷ In islets from diabetic animals, FGF21 treatment boosted both the amount of stored insulin and the ability of those cells to secrete insulin in response to glucose.⁷

More recent work has explored a specific signaling loop: glucagon, released by the pancreatic alpha cells, reaches the liver and stimulates FGF21 production, and the FGF21 then supports beta-cell regeneration. In a mouse model of type 2 diabetes, blocking the glucagon receptor with an antibody prompted the liver to make more FGF21, which in turn increased beta-cell numbers. When FGF21 was genetically deleted, or specifically knocked out in the liver, this regenerative effect was weakened.⁸ Human islet studies have added to the picture: chronic FGF21 treatment enhanced glucose-stimulated insulin secretion in islets from donors with glucose intolerance.⁹ The implication is that a healthy liver actively helps maintain the pancreas’s insulin-producing capacity, and liver disease could compromise that support.

Shared Plumbing and Acid Neutralization

Beyond the portal bloodstream, the liver and pancreas are physically connected through the biliary and pancreatic duct systems. The common bile duct, which carries bile from the liver and gallbladder, and the main pancreatic duct typically merge before emptying into the duodenum at the ampulla of Vater. Anatomic variants exist: in some people, the two ducts never fully merge, resulting in two separate openings into the intestine.¹⁰ But in most individuals, the shared channel means that problems in one duct, such as a stone blocking the exit, can back up into both systems.

Both organs also respond to the same hormonal signal when food leaves the stomach. Secretin, released by the intestinal lining when it senses acid, stimulates both the pancreatic duct cells and the bile duct cells (cholangiocytes) to secrete bicarbonate-rich fluid.¹¹ This bicarbonate neutralizes stomach acid in the duodenum, protecting the intestinal lining and creating the right pH for digestive enzymes to work. In experiments on pigs, at physiologic secretin levels the liver actually produced more bicarbonate than the pancreas, a finding that surprised researchers who had long assumed the pancreas was the dominant source.¹² When the gut hormone cholecystokinin was added alongside secretin, both hepatic and pancreatic bicarbonate output increased further, but the liver’s contribution still exceeded the pancreas’s.¹²

How Gallstones Trigger Pancreatitis

The shared ductal anatomy creates a well-known vulnerability. Gallstones form in the gallbladder, a liver-associated organ, but the most common cause of acute pancreatitis is a gallstone becoming lodged at the point where the bile duct and pancreatic duct meet.¹³ For decades, the leading explanation was that a stuck stone forces bile to reflux into the pancreatic duct, triggering inflammation. The current understanding is somewhat different: the obstruction itself, by blocking the outflow of pancreatic juice, raises pressure inside the pancreatic duct and sets off a damaging cascade within the acinar cells of the pancreas.¹⁴

Experimental work in rats showed that even a single four-hour blockage of the shared duct caused a measurable rise in serum amylase, increased pancreatic swelling, and a redistribution of destructive enzymes inside acinar cells, bringing digestive enzymes and enzymes that activate them into the same compartment. Repeated short blockages, mimicking a stone that briefly jams and then passes, caused even more severe damage.¹⁵ This finding helps explain why people with small gallstones that repeatedly pass through the duct may be at higher risk than those with a single large stone that stays put in the gallbladder.

When Liver Disease Causes Diabetes

People with chronic liver disease, particularly cirrhosis, develop diabetes at rates far higher than the general population. This condition, called hepatogenous diabetes, is increasingly recognized as a distinct clinical entity rather than ordinary type 2 diabetes happening to coincide with liver disease.¹⁶ The mechanism involves both insulin resistance driven by the failing liver and eventual damage to pancreatic beta cells. Chronic inflammation, endotoxins leaking from the gut, and neurohormonal changes in cirrhosis first create severe insulin resistance, meaning the body’s tissues stop responding well to insulin. Over time, the toxic milieu also impairs beta-cell function, tipping the balance from glucose intolerance to frank diabetes.¹⁷

Additional contributors include sarcopenia (loss of muscle mass common in cirrhosis), disrupted gut bacteria, and elevated ammonia levels, all of which further impair glucose handling.¹⁷ These parallels with type 2 diabetes are striking, and a review of the pathogenesis found shared pathways involving insulin signaling disruption, fatty acid metabolism, and pro-inflammatory cytokines.¹⁸ Even nonalcoholic fatty liver disease, well short of cirrhosis, appears to affect beta-cell function. A large analysis found that people with NAFLD had lower beta-cell function relative to their degree of insulin resistance, and this impaired function was independently associated with both NAFLD presence and more severe liver fat accumulation.¹⁹

Fat That Accumulates in Both Organs

Just as fat can infiltrate the liver in NAFLD, it can accumulate in the pancreas, a condition sometimes called fatty pancreas or nonalcoholic fatty pancreas disease. Some researchers have suggested that a fatty pancreas may be the earliest visible sign of ectopic fat deposition, the process at the heart of metabolic syndrome.²⁰ The relationship between pancreatic fat and liver fat appears to run in both directions. A meta-analysis including over 49,000 people found that having a fatty pancreas was independently associated with NAFLD, with roughly two and a half times the risk.²¹ The same review noted that fatty pancreas was associated with more severe histological features of NAFLD, including the inflammatory form (steatohepatitis) and fibrosis staging, suggesting that pancreatic fat may actually drive liver disease progression.²¹

For someone diagnosed with fatty liver, this connection raises a practical question: is the pancreas affected too? And for clinicians, it suggests that screening for one condition may warrant looking at the other, particularly in patients with metabolic syndrome.

Portal Hypertension and the Pancreas

Advanced liver disease also affects the pancreas through a purely mechanical route. Cirrhosis raises pressure in the portal venous system, and that elevated pressure transmits back into the veins draining the pancreas. A recent study compared 41 patients with liver cirrhosis to 41 matched controls. The cirrhosis group had significantly lower levels of fecal elastase-1, a standard marker of pancreatic digestive enzyme output, and about 15% of them met criteria for exocrine pancreatic insufficiency, while none of the controls did.²² Ultrasound measurements showed that the pancreatic tissue was stiffer in cirrhosis patients, consistent with congestion and swelling. An autopsy component of the same study found that thicker pancreatic veins, a sign of chronic congestion, correlated with less functional enzyme-producing tissue.²² In plain terms, when the liver’s blood flow is backed up, the pancreas gets squeezed, and its ability to produce digestive enzymes suffers. Patients with advanced cirrhosis who develop unexplained digestive problems, particularly fatty or oily stools, may be dealing with pancreatic insufficiency caused not by a pancreatic disease but by their liver disease.

Iron Overload Damages Both Organs Together

Hereditary hemochromatosis, a genetic condition that causes the body to absorb too much iron, is a textbook example of one systemic problem striking both organs at once. Excess iron accumulates in the liver, causing inflammation and eventually cirrhosis, while the same iron deposits damage pancreatic beta cells. Roughly half of patients diagnosed with hemochromatosis develop diabetes because iron accumulation selectively destroys beta cells, impairing both insulin production and insulin release, while also contributing to insulin resistance.²³ The liver damage and the pancreatic damage compound each other: cirrhosis worsens insulin resistance while beta-cell loss removes the ability to compensate. Early detection and treatment with phlebotomy (regular blood removal to reduce iron stores) can prevent or slow damage to both organs, but once cirrhosis and diabetes are established, the damage is often only partially reversible.

IgG4-Related Disease

A more recently characterized condition illustrates the shared vulnerability of these organs from an immune perspective. Autoimmune pancreatitis (AIP) is frequently associated with narrowing of the bile ducts in the form of IgG4-related sclerosing cholangitis. In this condition, the same type of immune-mediated inflammation, characterized by infiltration of IgG4-positive cells, attacks both the pancreas and the bile duct system in and around the liver. Because the histologic features in the bile ducts mirror those in the pancreas, AIP is now considered a pancreatic manifestation of a broader entity called IgG4-related sclerosing disease, which can affect multiple organ systems.²⁴ This matters clinically because it can mimic pancreatic or bile duct cancer on imaging, leading to unnecessary surgery if the correct diagnosis is missed. Unlike cancer, it typically responds well to steroid therapy.

Pancreatic Cancer’s Affinity for the Liver

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, has a striking tendency to metastasize to the liver above all other sites. This is not simply because of proximity. The primary pancreatic tumor, and possibly even its precancerous precursors, secretes soluble factors and tiny extracellular vesicles that travel to the liver and begin remodeling it before any cancer cells arrive. These signals recruit immune-suppressing inflammatory cells, increase the permeability of liver blood vessels, and remodel the connective tissue scaffold, effectively preparing docking sites for tumor cells that will arrive later.²⁵

The connection also runs in the other direction: a pancreatic head tumor commonly compresses the common bile duct, causing obstructive jaundice. Because pancreatic cancer is often diagnosed late, up to 80% of patients with pancreatic head tumors are only candidates for palliative treatments aimed at relieving this bile duct obstruction rather than curing the cancer.²⁶ Stenting the blocked bile duct or surgically creating a bypass are among the most common procedures for these patients, underscoring how entangled the two organs’ anatomies are even at the end stage of disease.

Combined Transplantation

Perhaps the most dramatic clinical acknowledgment of the liver-pancreas relationship is the combined liver-pancreas transplant. This procedure is rare but has been performed in patients with conditions that destroy both organs simultaneously, such as cystic fibrosis. In CF, thick secretions progressively damage the pancreatic ducts and the bile ducts, leading to both pancreatic insufficiency (requiring enzyme supplements and often insulin) and liver failure. A case report described that combined transplantation in a CF patient restored both exocrine and endocrine pancreatic function, allowing the patient to stop both insulin injections and pancreatic enzyme supplementation, while eliminating the life-threatening complications of liver failure.²⁷ By replacing both organs together, surgeons could address not just the individual organ failures but the way those failures were compounding each other, a principle that follows logically from everything the liver and pancreas share.